Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm

Law firm Bragar Eagel & Squire is investigating GeneDx Holdings Corp. for potential securities law violations following the company's May 4, 2026 earnings report that revealed a $57.5 million operational loss, $65 million revenue guidance cut, and a $31.3 million goodwill write-down. GeneDx shares plummeted 50% from $67.93 to $34.51 on the news, citing lower-than-expected reimbursement rates and weak performance from its Fabric Genomics unit.